{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.0","upperLimit":"103.0","value":"72.0"},{"comment":"Insufficient number of events to determine the upper limit","groupId":"OG001","lowerLimit":"62.0","upperLimit":"NA","value":"71.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Transfusion independence was defined as the absence of any transfusion during any consecutive \"rolling\" 8-week time interval within the treatment period, ie, Days 1 to 56, Days 2 to 57 and so on. Longest duration of transfusion independence was estimated based on Kaplan-Meier model.","dispersionType":"95% Confidence Interval","groups":[{"description":"Luspatercept (ACE-536) was administered subcutaneously (SC) at a starting dose level of 1 mg/kg once every 21 days. Participants could be dose-titrated to 1.25 mg/kg, but the maximum total dose should not exceed 120 mg, total dose per administration during the Treatment Period, the Long-term Treatment Period, and Open-Label Treatment Period. BSC = Best Supportive Care","id":"OG000","title":"Luspatercept + BSC"},{"description":"Placebo (normal saline) was administered subcutaneously (SC) in volumes to match active treatment once every 21 days. BSC = Best Supportive Care","id":"OG001","title":"Placebo + BSC"}],"paramType":"MEDIAN","populationDescription":"All randomized participants who were transfusion independent for ≥ 8 weeks","reportingStatus":"POSTED","timeFrame":"From first dose through 3 weeks post last dose (up to approximately 218 weeks)","title":"Longest Duration of Transfusion Independence","type":"SECONDARY","unitOfMeasure":"Days"}